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Abstract
Background: Few studies have examined whether the healthcare needs of people living with rare diseases are
being met. This study explores the experiences of Australian adults living with rare diseases in relation to diagnosis,
information provision at the time of diagnosis, use of health and support services and involvement in research on
their condition.
Methods: The survey respondents are self-selected from the population of Australian residents aged 18 years and
over who are living with a rare disease. An online survey was implemented between July-August 2014. Purposive
snowballing sampling was used. The results are reported as percentages with significant differences between
sub-groups assessed using chi-squared analyses.
Results: Eight hundred ten responses were obtained from adults living with a rare disease. 92.1 % had a confirmed
diagnosis, of which 30.0 % waited five or more years for a diagnosis, 66.2 % had seen three or more doctors to get
a diagnosis and 45.9 % had received at least one incorrect diagnosis. Almost three quarters (72.1 %) received no or
not enough information at the time of diagnosis. In the 12 months prior to the survey, over 80 % of respondents
had used the services of a general practitioner and a medical specialist while around a third had been inpatients at
a hospital or had visited an emergency department. Only 15.4 % of respondents had ever used paediatric services,
52.8 % of these had experienced problems in the transition from paediatric to adult services. Only 20.3 % knew of a
patient registry for their condition and 24.8 % were informed of clinical trials.
Conclusions: These findings suggest that not all healthcare needs of people living with rare diseases are being met.
Structural changes to Australian healthcare systems may be required to improve the integration and coordination
of diagnosis and care. Health professionals may need greater awareness of rare diseases to improve the diagnostic
process and support to meet the information requirements of people newly diagnosed with rare diseases. Health
service use is likely higher than for the general population and further epidemiological studies are needed on the
impact of rare diseases on the healthcare system.
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Background
In terms of prevalence, a rare disease has been defined
as one that is present in fewer than one person in 2000
in a population [1, 2]. The range of rare diseases is very
broad and around 80 % are thought to be genetic in
origin [1, 3]. For example Alopecia areata is a complex
genetic, immune mediated disease that results in partial
to universal hair loss [4], while Kabuki syndrome is
caused by a single mutation in one of two genes, and
results in multiple congenital anomalies such as altered
facial features, skeletal anomalies, growth deficiency and
intellectual disability [5]. Although the aetiology and
symptoms show great diversity, there are some
commonalities across the range of rare diseases. For
example, rare diseases often involve multi system
dysfunction, require complex care, have no effective
treatment, and are incurable [6–8]. Many are also asso-
ciated with motor, sensory or intellectual impairment [9]
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and impose significant social, emotional and financial
burdens on people living with rare diseases, and their
carers and families [10, 11].
Stakeholder consultations with members of the
Australian rare diseases community have indicated that
common features across the range of rare diseases lead
to similar needs from the health system [12, 13]. This
includes access to a wide range of health and social
support services across primary, secondary and tertiary
sectors [13, 14], along with:
 timely and accurate diagnosis;
 timely post-diagnosis information to inform
decision-making about ongoing care;
 complex case management which requires access to
a range of specialists, services and programs;
 coordinated and integrated care so that there are no
gaps in service delivery across the lifespan, including
transitions from paediatric to adult care;
 access to health professionals who are aware of,
experienced with and knowledgeable about rare
diseases; and
 access to infrastructure to support clinical,
epidemiological and translational research, such as
patient registries.
There are few studies that have examined whether such
healthcare needs are being met for people living with rare
diseases. Two studies conducted in the United Kingdom
(UK) [10, 15] and Europe [8, 16] identify experiences of
delayed diagnosis, misdiagnosis, a lack of information pro-
vided at the time of diagnosis, a lack of care coordination,
problems with transition from paediatric to adult care and
the prescription of incorrect medications. Anecdotally,
Australians living with rare diseases have described similar
experiences to those identified internationally. Yet to date
there has only been a single published study with a small
sample size and coverage restricted to paediatric patients
diagnosed with genetic metabolic disorders. This study
surveyed 30 families as a pilot study and found that 52 %
had consulted three or more doctors before receiving a
correct diagnosis and 43 % felt diagnosis was delayed [14].
The purpose of the present study was to explore the
healthcare experiences of adults living with a rare disease
in Australia. The Australian healthcare system includes a
mix of public and private health services. There are no
officially recognised centres of expertise for rare diseases,
although some disease-specific clinics do exist. There is
no national plan for rare diseases and only one state,
Western Australia, has adopted a jurisdictional strategic
framework for rare diseases [17]. Within this context, the
objectives of the study were to examine experiences of
diagnosis, perceptions of the information provided at the
time of diagnosis, availability and use of health and
support services, experiences during the transition from




The survey was hosted online using the SurveyMonkey
platform (SurveyMonkey Inc. Palo Alto, USA). The survey
instrument was adapted with permission from the survey
developed by Rare Diseases UK [10, 15]. Some modifica-
tions were made to ensure that the questions were rele-
vant in the Australian context, particularly relating to the
primary, secondary and tertiary structure of the Australian
healthcare system. A schematic diagram of the survey
instrument is provided at Fig. 1. The full survey instru-
ment is available from the authors upon request.
The survey instrument contains a majority of quanti-
tative, close-ended questions with defined response
categories. A smaller number of questions asked partic-
ipants to provide qualitative information and for these
an open-ended text box was provided. At the conclu-
sion of each survey section, participants were also given
the opportunity to provide any other comments they
had on the section topic. Only data from the quantita-
tive questions are reported in this paper.
The first section of the survey was used to obtain con-
sent and to determine participant eligibility. Participants
were provided with information about the survey, in-
cluding the purpose, the agencies conducting the study
and assurance around anonymity and aggregation of
data for reporting purposes. They were then advised that
by clicking the “next” button they were consenting to
participate in the survey. As the survey was completed
anonymously, once data was submitted by clicking the
“submit” button at the end of the survey it was not
possible to withdraw individual respondents’ data.
The demographic section of the survey asked partici-
pants for information including gender, age and state of
residence, the rare disease being lived with and the type of
diagnosis that had been received (i.e., confirmed, uncon-
firmed or no diagnosis). Participants were also asked to
rate their health, on a 5 point scale from excellent to poor.
This question has previously been shown to be a reliable
measure of general health [18] and is significantly associ-
ated with the relative risk of mortality [19].
The main body of the survey had four sections meas-
uring key aspects of the health care experience, namely
experiences of diagnosis, access to and use of health and
support services, transition from paediatric to adult care
settings and participation in research.
Survey sampling
Those eligible to complete the survey were Australian
residents aged 18 years or older who are living with a
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rare disease. Carers or paid support workers of people
meeting these criteria were also invited to complete the
survey, if the person living with a rare disease did not
have the intellectual and/or physical capability to
complete the survey themselves. The study was limited
to adults living with rare diseases for two reasons.
Firstly, the authors were aware that a survey of the
healthcare experiences of children was being conducted
simultaneously and did not want to over-burden the
families and carers of children living with rare diseases
with two similar surveys. Secondly, targeting the adult
population enabled us to examine issues outside the
paediatric healthcare system such as diagnosis and
transition to using adult health services.
Fig. 1 Schematic diagram of the survey instrument. Compulsory questions that lead participants to be skipped to particular sections within the
survey, together with their possible answers are shown in boxes
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To our knowledge a complete sample frame of all adults
living with a rare disease in Australia does not exist.
Unknown is the total number of people living with a rare
disease, their contact details and their socio-demographic
characteristics such as age, gender, highest education level
and location of residence. For these reasons, purposive
snowball sampling was used for this study. A link to the
online survey was distributed via the networks and mailing
lists of the Office of Population Health Genomics, within
the Western Australian Department of Health and the four
peak bodies in the Australian rare and genetic disease
sector, namely Rare Voices Australia, Genetic Alliance
Australia, Genetic Support Network Victoria and the
Genetic and Rare Diseases Network. The survey link was
initially distributed to over 300 patient support groups
across Australia, as well as individuals registered with any
of the collaborating organisations. Recipients of emails
were asked to forward the link on to other people who
were eligible for the survey. Because of the potential for
participants to receive more than one invitation to partici-
pate, survey responses were limited to one per computer.
Data were collected over a six week period during July-
August 2014.
Data analysis
SAS 9.2 survey analysis procedures for frequency tables
were used to analyse the survey data (SAS Institute Inc.
Cary, USA). The results are reported as percentages.
Differences in responses associated with demographics
were assessed for significance using chi-squared analyses.
Results
Sample characteristics
In total 1014 completed surveys were received. These were
initially examined to confirm whether or not the diseases
that respondents had reported having were rare. Alterna-
tive names and spellings were checked by referring to the
Orphanet database of rare diseases (www.orpha.net). If the
disease was listed in Orphanet with a prevalence of 1 in
2000 or less the respondent was deemed to be living with a
rare disease. On this basis, 810 respondents were consid-
ered to be living with a rare disease. Most of the remaining
respondents (n = 172) were living with a disease that typic-
ally has similar characteristics to a rare disease in that it is
chronic and debilitating, but is more prevalent than 1 in
2000 people in the population. Others were removed from
the study due to not meeting the age criteria, that is, they
were aged less than 18 years.
Of the 810 respondents who were considered to be
living with a rare disease, 92 % had received a confirmed
diagnosis. For the purposes of this study, a confirmed
diagnosis is defined as a diagnosis that the doctor and pa-
tient are certain is correct based on a genetic (or other) test
or clinical manifestation. Six percent had an unconfirmed
diagnosis, defined as a diagnosis that the doctor and
patient think is most likely to cause the symptoms experi-
enced, but are not certain. The remainder had no diagnosis
(1.5 %) or were unsure (0.5 %). In order to ensure we were
examining the healthcare experiences of adults living with
a rare disease, only those respondents with a confirmed
diagnosis of a rare disease are included in the findings
reported below.
Table 1 shows the demographic characteristics of
survey respondents living with a confirmed rare disease.
Responses were received from people located in all states
and territories of Australia, and their numbers were





Sex (n = 744)
Female 568 76.3
Male 176 23.7
Age groups (n = 234)
18–34 years 61 26.1
35–64 years 129 55.1
65 years and over 44 18.8
State of residence (n = 741)
New South Wales 212 28.6
Victoria 182 24.6
Queensland 159 21.5
Western Australia 92 12.4
South Australia 44 5.9
Australian Capital Territory 25 3.4
Tasmania 23 3.1
Northern Territory 4 0.5
Role of person answering the survey (n = 741)
A paid support worker 6 0.8
A person living with a rare disease. 661 89.2
A relative/carer of a person with a rare disease 74 10.0
Other 0 0





Self-reported health status (n = 743)
Excellent 25 3.4
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generally in proportion to the size of the population in
each state and territory [20]. The age of respondents
ranged from 18 to 87 years of age, with a median age of
47 years. The majority of respondents were female
(76.3 %) and were themselves living with a rare disease
(89.2 %), as opposed to being a relative/carer (10.0 %) or
paid support worker (0.8 %). Almost one in five (18.6 %)
reported their health as poor. Respondents reported
living with up to four different rare diseases although
84 % of respondents reported living with only one rare
disease (Table 1).
A total of 185 rare diseases were represented (sub-types
of a rare disease were combined together). Ninety-nine
diseases had only one respondent, while the greatest num-
ber of responses for a single disease group (n = 52) was for
Ehlers-Danlos syndrome, which has multiple sub-types.
Table 2 provides a list of the diseases represented in the
survey, as organised by nosological group based on the
linearized Orphanet classifications [21]. The survey out-
comes were not analysed by nosological disease groups,
since there were 21 groups of diseases and the size of the
sample in some groups was too small to detect significant
differences in responses.
Experiences of diagnosis
Table 3 shows that of the respondents with a confirmed
diagnosis, 17.4 % had been diagnosed as children, that is
between birth and 17 years of age, although this was
higher for men compared to women (24.6 % versus
15.0 %, p < 0.01). A quarter (25.2 %) of respondents were
diagnosed within three months of first seeking medical
help, although this was higher for those diagnosed as
children compared to those diagnosed as adults (43.4 %
versus 21.8 %, p < 0.001). Around half the respondents
(51.2 %) waited 1 year or more for a diagnosis, with
almost one-third (30.0 %) waiting five or more years.
Two-thirds of respondents (66.2 %) had consulted three
or more doctors to get a confirmed diagnosis (Table 3).
The percentage was lower for people diagnosed as children
compared to those diagnosed as adults (50.4 % versus
78.6 %, p < 0.001) and for men compared to women
(57.9 % versus 68.2 %, p < 0.05). Almost half of the respon-
dents (45.9 %) had received at least one incorrect diagno-
sis, that is, they were initially told they had a condition but
were subsequently told they did not have that condition.
This occurrence of incorrect diagnosis was lower for
Table 2 Diseases represented in the confirmed rare disease group






Rare abdominal surgical disease 1 0.1 1
Rare allergic diseases 17 2.3 1
Rare bone disease 5 0.7 4
Rare circulatory disease 1 0.1 1
Rare developmental defect during
embryogenesis
80 10.7 37
Rare endocrine diseases 39 5.2 10
Rare eye disease 1 0.1 1
Rare gastroenterologic disease 21 2.8 6
Rare gynecologic or obstetric
disease
1 0.1 1
Rare hematologic disease 21 2.8 7
Rare hepatic disease 9 1.2 2
Rare immune disease 41 5.5 7
Rare inborn errors of metabolism 50 6.7 13
Rare neoplastic disease 11 1.5 8
Rare neurological disease 263 35.3 45
Rare otorhinolaryngologic disease 3 0.4 1
Rare renal disease 6 0.8 2
Rare respiratory disease 55 7.4 4
Rare skin disease 22 3.0 12
Rare systemic or rheumatologic
disease
90 12.1 19
Unclassified 9 1.2 3





Age at diagnosis (n = 732)
0–17 years 127 17.4
18 years or more 605 82.6
Time to diagnosis (n = 718)
<3 months 181 25.2
3–12 months 169 23.5
1–5 years 153 21.2
5–10 years 147 20.5
>20 years 68 9.5
Number of doctors seen to get a confirmed




11 or more 90 12.2
Incorrect diagnosis (n = 737)
At least one incorrect diagnosis 338 45.9
No incorrect diagnosis 360 48.8
Unsure 39 5.3
Information on condition received (n = 742)
Received no information 141 19.0
Received some information but not enough 394 53.1
Received enough information 192 25.9
Unsure 15 2.0
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respondents diagnosed as children compared to those
diagnosed as adults (35.6 % versus 51.2 %, p < 0.01).
Information provision at the time of diagnosis
Around one in five respondents (19.0 %) had not re-
ceived any information about their condition at the time
of diagnosis (Table 3). Of the respondents who received
information, 50.0 % indicated that they understood all of
the information provided (Table 4). The vast majority of
those who received information were given this informa-
tion by a medical specialist (82.9 %). Respondents who
received information from a general practitioner (GP)
were less likely to say they received enough information
(16.4 %, p < 0.01) while those who received information
from a genetic counsellor were more likely to say they
received enough information (43.9 %, p < 0.05).
Almost one-third of respondents reported receiving
verbal information only (31.2 %) or printed material
(32.1 %) and 26.6 % received a referral to a website.
Those who received verbal information only were less
likely to report they had understood all of the informa-
tion provided (42.8 %, p < 0.05) and that they received
enough information (21.9 %, p < 0.001), while people re-
ferred to a website were more likely to report they had
understood all the information they were given (64.7 %,
p < 0.001) and that they had received enough informa-
tion (47.4 %, p < 0.001). Compared to respondents who
received only one source of information, those provided
with two or more sources of information were more
likely to report the information provided was enough
(43.3 % versus 22.1 %, p < 0.001) and that it was under-
stood (61.2 % versus 46.7 %, p < 0.01).
Preferred information formats, information sources,
knowledge and the use of support groups
Of the options provided in the survey, 77.6 % percent of
respondents reported that referral to a website was the
most preferred format of information on their condition
(Table 5), followed by social media (56.2 %), printed
materials such as brochures or leaflets (52.4 %) and
journal articles (49.3 %).
At the time of the survey, the main sources of informa-
tion available to respondents on their condition were
medical specialists (60.7 %), patient organisations (39.0 %)
and other people or families (35.1 %, Table 5). Six in ten
respondents (59.4 %) had a specific person they could
consult with questions on their condition however 27.3 %
did not think they now have sufficient knowledge of their
condition. Of those who did have someone to ask
questions, the vast majority said this person is a medical
specialist. In the 12 months prior to the survey, 53.5 % of
respondents had used the services of a patient organisa-
tion or support group.
Access to and use of healthcare and other services
Table 6 shows that the majority of respondents agreed
that they received sufficient medical support (66.4 %)
but fewer agreed they received sufficient social (34.1 %),
financial (14.5 %) and psychological (20.6 %) support. In
the 12 months prior to the survey, 8 in 10 respondents
had used the services of a GP (81.1 %) and a medical
specialist (81.4 %) at least once (Table 7), 40.3 % had
used an outpatients service or clinic, while around a
third had been inpatients at a hospital (28.0 %) or had
visited an emergency department (33.4 %). This level of
service use is higher than that reported for the general
population of Australians aged 15 years and older [22],
where 35 % had visited a medical specialist, 9 % had used
an outpatient service, 13 % had been an inpatient at
hospital and 12 % had used an emergency department.
Nearly four in ten (38.8 %) consulted three or more
specialists for their ongoing care yet only 9.2 % had a
designated care coordinator (Table 8). Similarly, 39.1 %
travelled more than 50 km to see their medical specialists,
while only 3.9 % had used telehealth services. One-fifth
(22.1 %) knew of a specialist centre for their condition and
the majority of these respondents had used that centre.
Overall, 37.0 % were satisfied with the adult services they
used while 25.2 % were dissatisfied and 37.8 % neither
satisfied nor dissatisfied.





Understanding of information provided (n = 578)
Did not understand all the information 289 50.0
Understood all the information 289 50.0
Who provided informationb (n = 578)
General practitioner 73 12.5
Medical specialist 486 82.9
Genetic counsellor 82 14
Allied health professional 16 2.7
Other 42 7.2
Format of information provided at diagnosisb
(n = 578)
Printed material (e.g., brochures, leaflet) 188 32.1
Referred to website 156 26.6
Social media 87 14.8
Journal article 79 13.5
Verbal onlyc 183 31.2
Other 9 1.5
aAmong respondents who received information at the time of
diagnosis (n = 586)
bMultiple responses reported
cRespondents were not given this option to choose. Instead it was nominated
as a response to the option ‘other’
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Experiences of paediatric services and the transition to
adult services
Fifteen percent of respondents had ever used paediatric
services (Table 8). Just over half of these respondents
(57.0 %) were satisfied with the care they had received
from paediatric services, while 10.6 % were dissatisfied
and 32.5 % were neither satisfied nor dissatisfied. Half of
respondents who had used a paediatric health service
were satisfied with the time between the last paediatric
visit and the first visit to adult services (49.5 %) while
25.2 % were dissatisfied. Half had experienced problems
in the transition from paediatric to adult services
(52.8 %). Transition is most often defined as “the pur-
poseful, planned movement of adolescents and young
adults with chronic physical and medical conditions
from child-centred to adult-oriented health care sys-
tems” [23].
Participation in research
Patient registries are sets of clinical and non-clinical data
stored in an organised, systemic manner [24]. They can
be used to build knowledge about rare disease diagnosis,
treatment and management, and enable access to clinical
trials of drug treatments and other therapies that are be-
ing developed [25, 26]. Only 20.3 % of survey respon-
dents knew of a patient registry for their condition, yet
88.6 % indicated they would join a registry if one existed
(Table 9). Of those respondents who know of a patient
registry for their condition, 90.6 % had joined that
registry.
One-quarter (24.8 %) of respondents reported they are
informed of clinical trials for their condition while fewer
agreed that they were given enough information on clin-
ical trials (16.6 %) or on research in general into their
condition (19.3 %). One-third (33.2 %) had participated
in research into their condition, with the most common





Preferred format for informationa (n = 746)
Referred to website 579 77.6
Social media 419 56.2
Printed material (e.g., brochures, leaflet) 391 52.4




Main source of informationa (n = 746)
Medical specialist 453 60.7
Patient organisation 291 39.0
Other people or families 262 35.1
Own research 112 15.0
GP 86 11.5
Genetic councilor 44 5.9
Allied health professional 38 5.1
Other 202 27.1




Don’t know 104 14.0
Have a specific person to ask questions about
condition (n = 737)
Yes 438 59.4
No 299 40.6
Have used a patient support group in past




Several times 98 15.8
Once or twice 72 11.6
Never 288 46.5
aMultiple responses reported




Medical (n = 624) 66.4 18.9 14.6 –
Social (n = 709) 34.1 25.4 40.6 –
Financial (n = 725) 14.5 21.1 61.0 3.4
Psychological (n = 727) 20.6 26.3 50.3 2.8
Table 7 Health services used at least once in the 12 months
prior to survey
Service used na % of total
sample
Medianb Modeb Rangeb
General Practitioner 605 81.1 6 2 1–100
Allied Health 286 38.3 5 2 1–250
Medical Specialist 607 81.4 2 2 1–365
Emergency Department 249 33.4 4 1 1–32
Hospital Outpatients/Clinics 301 40.3 4 1 1–100
Hospital Inpatients 209 28.0 2 1 1–365
Dental Services 236 31.6 2 1 1–31
Mental Health Services 207 27.7 5 1 1–52
Alternative Health Services 173 23.2 5 1 1–175
aThe number of respondents living with a confirmed diagnosis who used a
service at least once
bAmong those who used the service at least once
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form of participation being the provision of biological
samples for research, followed by being on a registry and
participating in a clinical trial.
Discussion
Consistent with previous studies conducted in the
United Kingdom and Europe [8, 10, 16, 27], around half
of the respondents in the current study waited one year
or more to be diagnosed with a rare disease, with almost
a third waiting five or more years. Two-thirds consulted
three or more doctors before receiving a confirmed diag-
nosis and almost half were given an incorrect diagnosis
prior to their final diagnosis. This is problematic in that
the absence of an early, accurate diagnosis can contrib-
ute to unnecessary or delayed treatment, poorer health
outcomes, reduced quality of life, unnecessary hospital
admissions and thus inefficient use of health system re-
sources [8, 16, 28–30].
It can be assumed that clinicians work hard to deliver
timely, accurate diagnoses for their patients and that a
long wait for diagnosis can, at least in part, be attributed
to the nature of rare diseases. Most are complex with
multi-system dysfunction and thus may require a diag-
nostic process that involves multiple medical specialties
and a systematic method of precluding conditions before
arriving at a final diagnosis. However it is also possible
that structural features within health systems could con-
tribute to inefficiencies and gaps in the diagnostic
process.
Fragmentation and the siloed nature of Australian
health systems, organised by medical specialties, could
lead to lack of communication between specialties and
the experience of patients not being considered as a
‘whole person’, both at the time of diagnosis and during
ongoing care and disease management. This possibility
suggests that components of the health system need to





Number of specialists seen for ongoing care




More than 6 37 5.1
Don’t know 9 1.2
Designated care coordinator (n = 742)
Yes 68 9.2
No 648 87.4
Don’t know 26 3.5
Distance travelled to see medical specialists
(n = 734)
<20 km 242 33.0
20–50 km 204 27.8
51–100 km 88 12.0
101–200 km 68 9.2
201–500 km 59 8.0
>500 km 73 9.9
Use telehealth services (n = 741)
Yes 29 3.9
No 697 94.0
Don’t know 15 2.0





Overall satisfaction with adult health services
(n = 674)
Very satisfied 70 10.4
Satisfied 179 26.6
Partly satisfied and partly dissatisfied 255 37.8
Dissatisfied 84 12.5
Very dissatisfied 86 12.7
Had ever used paediatric services (n = 746)
Yes 115 15.4
No 606 81.2
Don’t know 25 3.4
Overall satisfaction with paediatric health
servicesa (n = 114)
Very satisfied 26 22.8
Satisfied 39 34.2
Table 8 Health service experiences (Continued)
Partly satisfied and partly dissatisfied 37 32.5
Dissatisfied 6 5.3
Very dissatisfied 6 5.3
Satisfied with time between last paediatric
and first adult visita (n = 103)
Yes 51 49.5
No 26 25.2
Don’t know 26 25.2
Problems in transition from paediatric to
adult servicesa (n = 108)
Yes 57 52.8
No 38 35.2
Don’t know 13 12.0
aAmong respondents who had ever used paediatric services (n = 115)
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be better integrated and individual care for people living
with rare diseases to be better coordinated [29, 31, 32].
Aligned with this, the role of multi-disciplinary centres
of expertise in rare disease requires exploration in the
Australian context.
Internationally multi-disciplinary centres have been
promoted as mechanisms to bring together health profes-
sionals from a range of medical and allied health disci-
plines. The aim is to provide a team-based approach that
integrates services for diseases diagnosis, follow-up and
management and enable a continuum of care and care
coordination for people living with rare diseases [33–35].
Mental health professionals should be considered a key
part of a multi-disciplinary approach, given half of our
respondents’ perceived they did not receive sufficient
psychological support.
Structural issues may be particularly pertinent for
adult health services when compared with paediatric
services. The present study found that respondents
diagnosed as children were more likely to have been
diagnosed within three months, to see fewer doctors
before receiving a confirmed diagnosis and they were
less likely to receive an incorrect diagnosis. While this
could be due to the nature of the diseases and symptoms
that onset in childhood compared to adulthood, it could
also be due to differences in the structure and operations
of paediatric and adult care settings in Australia. Paedi-
atric settings are generally more likely to involve family
and carers, have shorter wait times, fewer patients,
general paediatricians who cut across specialty areas,
multi-disciplinary teams and specialists knowledgeable
in rare diseases.
The differences in care settings may also contribute
to the problems experienced by a significant number of
respondents who needed to transition from paediatric
to adult care. Poor transition can influence patterns of
integration into adult health services (e.g., not making
or keeping appointments) and reduce adherence to
treatments, both of which can result in poorer health
outcomes [36]. To the extent that there is a lag
between the time of transition and when the survey
was completed, it is possible that respondent views on
the transition experience are associated with recall bias.
Thus the reliability of this data must be approached with
caution. However, previous Australian findings [37] have
also identified the need for improved transition for people
living with rare diseases, including better preparation and
planning for transition, continuity and coordination of
care including the sharing of patient records and medical
history, flexibility to allow the involvement of parents and
carers and access to transition coordinators.
Health professionals may need greater awareness of rare
diseases in order to improve the diagnostic process, and
support to meet the information requirements of people
newly diagnosed with rare diseases. With 5000 or more
rare diseases, it is unrealistic to expect that health profes-
sionals would know about every rare disease. However,





Would join registry if one existed (n = 741)
Yes 657 88.6
No 13 1.8
Don’t know 71 9.6
Know of a patient registry (n = 737)
Yes 150 20.3
No 587 79.7





Would prefer not to say 1 0.7
Informed of clinical trials (n = 741)
Yes 184 24.8
No 515 69.5
Don’t know 42 5.7




Don’t know 120 16.5
Given enough information about research in
general (n = 735)
Yes 142 19.3
No 520 70.8
Don’t know 73 9.9




Type of research participationb,c (n = 248)
Being on a registry 90 36.3
Clinical trial 81 32.7
Recruiting others to participate in clinical trials 17 6.9
Providing samples for research 139 56.0
Patient representative 10 4.0
Survey 25 10.1
Other 27 10.9
aAmong those who know of a patient registry for their condition (n = 150)
bAmong those who had participated in research (n = 260)
cMultiple responses reported
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education could be provided to reinforce to health profes-
sionals that when they see a patient whose symptoms they
can’t explain, usual practice is to ask whether the cause
could be a rare disease. This approach to education seems
appropriate since patients have reported that accelerating
a correct diagnosis requires the crucial step of recognising
their disease is not one frequently encountered but
possibly a rare disease [25].
When compared to data on Australians aged 15 years
and older from the Australian Health Survey [22], the
respondents to the current survey appear more likely to
have seen a medical specialist, been an inpatient at
hospital, used an outpatient service or used an emer-
gency department. This suggests that health service use
may be higher among people living with rare diseases
compared to the general population. This claim is
supported with a study by Dye et al. (2011) which found
that adults living with rare genetic disorders had
increased numbers of hospital admissions and longer
lengths of stay [38]. Thus the health system costs
attributable to rare diseases may be disproportionately
high compared to the size of the population living with
rare diseases. Information on the impact of rare diseases
on the health system is critical for planning services that
respond to the needs of people living with rare diseases
and epidemiological studies are required to investigate
this further.
In this study respondents indicated an overwhelming
desire to be involved in research into their condition. In
particular, 90 % respondents indicated that they would
join a patient registry if one existed for their condition.
In Australia, interest in patient registries has grown
significantly among clinicians, researchers, industry and
patient organisations since registries facilitate research
into rare diseases and are particularly important in
supporting patient access to local, national and inter-
national clinical trials of new drug treatments and ther-
apies [26, 39]. While there are numerous disease specific
registries in Australia, these tend to be siloed and lack
interoperability. There have been calls for a national
registry in Australia for all rare diseases, similar to those
developed in other countries [40]. Based on the findings
of this study, people living with rare diseases would
seem likely to join a disease-specific and/or a national
registry, if the existence of such a registry is communi-
cated to them.
It is not possible to determine the generalizability of
the results from this study to the total population of
people living with a rare disease. There is a paucity of
evidence regarding the total number of people living
with a rare disease in Australia, and their characteristics
such as gender, age distribution, level of education and
socio-economic status are unknown. Respondents to this
study were self-selected after receiving an email about
the survey, most likely from a patient support organisa-
tion that was on the distribution list of one or more of
the study partners. Thus people without links to a
patient support organisation that was known to the
study partners will be under-represented in the survey
respondents, as will those without a computer/email
address and those with lower e-health literacy.
It is assumed that the high proportion of female
respondents to the study is over-representative. This
may be due to the fact that women are more likely to
respond to surveys or the fact that people were recruited
to the study through patient organisations to which
women may be more likely to belong. While this may bias
the survey findings, comparisons to male respondents
indicated there were few areas of reported healthcare
experiences with significant differences between men and
women. An exception to this was the higher percentage of
men being diagnosed with a rare disease in childhood and
this warrants further investigation.
In relation to age, while it was compulsory for respon-
dents to answer whether or not the person living with a
rare disease was aged 18 years or over, it was not compul-
sory to provide details of actual age in years and relatively
few respondents chose to do so (n = 257, 31.7 % of the
sample). We are not sure why this is the case but as a
result it was unreliable to conduct an analysis of survey
outcomes by age groups. It is possible that outcomes
would be different across age groups, given that health
services have likely changed over the course of time, and
this could be further investigated.
Sample bias may also exist in relation to the type of
diseases which were represented among the study respon-
dents. Some conditions, such as Ehlers-Danlos syndrome,
were over-represented in relation to the total sample size.
Similarly, it’s possible that more severe disorders, such as
those that lead to major incapacity and/or early death, are
under-represented. Despite this, survey respondents did
represent a range of rare diseases and commonalities in
healthcare experiences were identified that cut across
disease types. This suggests that considering rare diseases
as a collective group is an efficient way for health service
providers and policy-makers to respond to the public
health issue of rare diseases. In a health system that is
oriented towards more common diseases, a collective view
should serve to raise the profile of rare diseases and is
likely to result in less duplication of efforts and resources
across the range of rare diseases.
Conclusion
This study of 746 survey respondents addresses a gap in
the literature regarding the healthcare experiences of
Australian adults living with a confirmed rare disease
and suggests that not all of their healthcare needs are
being met. In line with the study findings, calls for a
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national plan for rare diseases in Australia [7, 12, 13, 41]
have suggested that a national plan should support:
patient-centric, integrated, coordinated, multi-disciplinary
care; the information needs of people living with rare
diseases, their carers, families and health professionals;
training for health professionals so that they can better
identify rare diseases; and the development of research
infrastructure such as patient registries which are easily
accessible for people living with rare diseases. The current
study provides some much needed evidence to support an
emphasis on these issues in national planning for rare
diseases in Australia.
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